Regulus Therapeutics Inc (NASDAQ:RGLS) – Equities research analysts at Wedbush decreased their Q2 2019 earnings per share (EPS) estimates for Regulus Therapeutics in a research report issued to clients and investors on Thursday, May 16th. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter, down from their previous forecast of ($0.19). Wedbush currently has a “Hold” rating and a $1.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q3 2019 earnings at ($0.37) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.32) EPS, Q1 2020 earnings at ($0.35) EPS, Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.37) EPS, Q4 2020 earnings at ($0.38) EPS, FY2020 earnings at ($1.46) EPS, FY2021 earnings at ($1.66) EPS and FY2022 earnings at ($1.89) EPS.

Several other analysts also recently weighed in on RGLS. Wells Fargo & Co reduced their target price on Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating for the company in a report on Tuesday, March 19th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Friday, March 29th. Finally, ValuEngine downgraded Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $1.06.

Regulus Therapeutics stock opened at $1.31 on Monday. Regulus Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $9.48. The stock has a market capitalization of $27.53 million, a PE ratio of -0.23 and a beta of 2.26.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.15) by $0.84. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 526.10%. The business had revenue of $6.78 million during the quarter, compared to the consensus estimate of $0.02 million.

In related news, Director Pascale Witz acquired 29,630 shares of Regulus Therapeutics stock in a transaction on Tuesday, May 7th. The stock was purchased at an average cost of $1.08 per share, with a total value of $32,000.40. Following the purchase, the director now directly owns 37,849 shares in the company, valued at $40,876.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Peter J. Barris acquired 1,136,704 shares of Regulus Therapeutics stock in a transaction on Tuesday, May 7th. The shares were bought at an average cost of $1.08 per share, with a total value of $1,227,640.32. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,199,528 shares of company stock valued at $1,295,490 and have sold 68,107 shares valued at $83,478. 5.40% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of RGLS. Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 396.3% during the 3rd quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 475,512 shares during the last quarter. Virtu Financial LLC purchased a new stake in Regulus Therapeutics during the 1st quarter valued at approximately $68,000. Jane Street Group LLC purchased a new stake in Regulus Therapeutics during the 1st quarter valued at approximately $64,000. Finally, Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 32.8% during the 1st quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,751 shares during the last quarter. 25.17% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Further Reading: What is range trading?

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.